An observational study in Larynx Cancer, Pharynx Cancer and Pharyngocutaneous Fistula, sponsored by MiMedx Group, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-13.
Sponsored by MiMedx Group, Inc. · Observational
Among 131 studies in Laryngeal Neoplasms with a site in United States — 33 open to participants now, 46 under way, 3 of them phase 3. Laryngeal Neoplasms · United States.
Among the 131 studies in Laryngeal Neoplasms with a site in United States, this one is the 19th largest by enrollment of the 20 observational ones that give a count, is one of 7 that started in 2018, is one of 20 observational ones, and was the 81st registered.
257 studies on the registry are indexed under Laryngeal Neoplasms; 68 are open to participants now.
Browse Laryngeal Neoplasms studies →33 of the 131 studies in Laryngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Metaclipse Therapeutics Corporation · Sites in United States
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18–89
National Cancer Institute (NCI) · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Laryngeal Neoplasms studies recruiting now, 41 (73%) set no upper age limit and 6 (11%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 52 · Phase 3 8 · Phase 4 3
First in 1995; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 100 across 60 observational studies indexed under Laryngeal Neoplasms.
Median enrollment 40 across the 105 interventional studies, 252 across the 20 observational. Of the 78 that completed or were terminated, 30 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 131 have an industry lead sponsor. The 10 most frequent:
MiMedx Group, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
MiMedx Group, Inc. has 1 study filed under Laryngeal Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Laryngeal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03759431Centre hospitalier de l'Université de Montréal (CHUM)Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer | 2026-12-12 |
| NCT01473784Ohio State University Comprehensive Cancer CenterTransoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck | 2026-12-31 |
| NCT05337631University Hospital FreiburgSpecial Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
| NCT06532279NRG OncologyTesting the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 131 studies in Laryngeal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial aims to determine if intra-operative use of human dehydrated amnion chorion allograft improves post-operative patient healing outcomes.
This study is to determine if intra-operative use of Amnio-Fix improves post-operative patient healing outcomes after laryngectomy and/or pharyngectomy.
This is a single-center, matched case registry. The medical records of approximately 40 patients meeting all documentation and eligibility requirements will comprise the retrospective cohort. A total of 40 subjects will be enrolled prospectively at Mount Sinai Hospital. It is expected that the majority of the subjects will be recruited through the investigators' standard admission practices. All subjects selected for the study will not be excluded because of race or ethnicity and all efforts will be made to adequately represent the patient population in the area in which they are chosen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Dehydrated human amnion/chorion membrane
Drug page: Dehydrated Human Amnion/Chorion Membrane
Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
Incidence of Pharayngocutaneous Fistula Development (PCF)
Incidence of PCF developement necessitating intervention within the 60 day time point.
Time frame: 60 days
Ran from Mar 2018 to primary completion in Mar 2019, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.